Precigen (NASDAQ:PGEN) CFO Harry Jr. Thomasian Sells 171,429 Shares of Stock

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian sold 171,429 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $5.53, for a total value of $948,002.37. Following the transaction, the chief financial officer owned 354,535 shares of the company’s stock, valued at approximately $1,960,578.55. This represents a 32.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

• On Monday, June 29th, Harry Jr. Thomasian sold 28,571 shares of Precigen stock. The stock was sold at an average price of $5.78, for a total value of $165,140.38.
• On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total value of $182,614.24.

Precigen Stock Performance

PGEN traded down $0.45 during trading hours on Wednesday, hitting $5.25. The company’s stock had a trading volume of 7,446,304 shares, compared to its average volume of 4,558,847. The company has a 50-day simple moving average of $4.40 and a 200 day simple moving average of $4.21. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. The firm has a market capitalization of $1.87 billion, a PE ratio of -4.45 and a beta of 1.06. Precigen, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $6.04.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The company had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. As a group, sell-side analysts expect that Precigen, Inc. will post -0.02 EPS for the current year.

Institutional Trading of Precigen

A number of hedge funds and other institutional investors have recently modified their holdings of PGEN. Xponance LLC lifted its holdings in shares of Precigen by 21.3% during the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 2,993 shares in the last quarter. Composition Wealth LLC increased its stake in Precigen by 16.5% in the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 3,000 shares in the last quarter. Intech Investment Management LLC raised its holdings in Precigen by 5.2% during the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock worth $263,000 after buying an additional 3,137 shares during the period. Finally, Cetera Investment Advisers raised its holdings in Precigen by 0.9% during the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after buying an additional 3,250 shares during the period. Institutional investors own 33.51% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PGEN shares. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Citigroup reissued an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. HC Wainwright boosted their price target on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Citizens Jmp upped their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. Finally, Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $12.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.